Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS906 in PNH patients with sub-optimal response to ravulizumab
NCT05972967Phase 2Completed
- Sponsor
- Omeros Corporation
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Omeros Corporation. Started Mar 2023; status: completed.
02
Drugs
zaltenibart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05972967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972967.